4,630 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Everence Capital Management Inc.

Everence Capital Management Inc. acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the fourth quarter, Holdings Channel reports. The firm acquired 4,630 shares of the company’s stock, valued at approximately $203,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of Revolution Medicines by 55.8% in the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after acquiring an additional 222 shares during the last quarter. Captrust Financial Advisors boosted its position in Revolution Medicines by 4.1% during the 3rd quarter. Captrust Financial Advisors now owns 8,459 shares of the company’s stock valued at $384,000 after buying an additional 337 shares during the period. Amalgamated Bank grew its holdings in Revolution Medicines by 7.4% in the 2nd quarter. Amalgamated Bank now owns 5,272 shares of the company’s stock worth $205,000 after acquiring an additional 365 shares during the last quarter. KBC Group NV increased its position in shares of Revolution Medicines by 12.9% in the third quarter. KBC Group NV now owns 3,221 shares of the company’s stock valued at $146,000 after acquiring an additional 368 shares during the period. Finally, Seven Eight Capital LP boosted its holdings in shares of Revolution Medicines by 1.6% during the second quarter. Seven Eight Capital LP now owns 69,602 shares of the company’s stock worth $2,701,000 after purchasing an additional 1,108 shares during the period. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RVMD. Needham & Company LLC restated a “buy” rating and set a $68.00 price target on shares of Revolution Medicines in a research report on Tuesday, December 3rd. HC Wainwright raised their price target on Revolution Medicines from $64.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. JPMorgan Chase & Co. lifted their target price on shares of Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a report on Tuesday, December 3rd. Piper Sandler boosted their price objective on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, UBS Group raised their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Revolution Medicines presently has a consensus rating of “Buy” and an average price target of $66.25.

Revolution Medicines Price Performance

Shares of RVMD opened at $44.42 on Friday. The company’s fifty day moving average price is $50.44 and its 200-day moving average price is $46.54. The firm has a market capitalization of $7.47 billion, a PE ratio of -12.37 and a beta of 1.46. Revolution Medicines, Inc. has a 1-year low of $25.93 and a 1-year high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, November 6th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). During the same quarter in the prior year, the business posted ($0.99) EPS. As a group, research analysts anticipate that Revolution Medicines, Inc. will post -3.5 EPS for the current fiscal year.

Insider Activity

In other Revolution Medicines news, Director Thilo Schroeder bought 1,304,347 shares of the stock in a transaction on Thursday, December 5th. The shares were bought at an average price of $46.00 per share, with a total value of $59,999,962.00. Following the purchase, the director now directly owns 2,096,612 shares in the company, valued at $96,444,152. This trade represents a 164.64 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Jack Anders sold 2,635 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the transaction, the chief financial officer now owns 96,470 shares in the company, valued at $4,379,738. The trade was a 2.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,344 shares of company stock worth $1,672,782 over the last three months. 8.00% of the stock is currently owned by corporate insiders.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.